1
Total investments
0
Early stage
1
Mid stage
0
Late stage
1y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor in Residence
Nov 2025
Yale innovation has the potential to change the world. Launched by Yale University in 2022, Yale Ventures seeks to foster and accelerate a vibrant entrepreneurship and innovation ecosystem that increases support, resources, and opportunities for Yale innovators—faculty and students—as they translate their ideas and discoveries into new ventures that will positively impact the worlds greatest challenges.
Experience · 5 entries
All (5)
Investments (1)
Founder (1)
2025
Investor in Residence
Nov 2025
Yale innovation has the potential to change the world. Launched by Yale University in 2022, Yale Ventures seeks to foster and accelerate a vibrant entrepreneurship and innovation ecosystem that increases support, resources, and opportunities for Yale innovators—faculty and students—as they translate their ideas and discoveries into new ventures that will positively impact the worlds greatest challenges.
2022
Associate Director of Strategy and Portfolio Analytics
Oct 2022
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures.
The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
2018
Founder and Principal Craft Science Consulting-Pro bono
Dec 2018
Since 1965, the University of California, Irvine has combined the strengths of a major research university with the bounty of an incomparable Southern California location. As a U.S. News & World Report top 10 public university, UCI’s unyielding commitment to rigorous academics, cutting-edge research, and leadership and character development makes the campus a driving force for innovation and discovery that serves our local, national and global communities in many ways.
With more than 37,000 students, 1,497 faculty members and 11,622 staff, UCI is among the most dynamic campuses in the University of California system. Increasingly a first-choice campus for students, UCI ranks among the top U.S. universities in the number of undergraduate applications and continues to admit freshmen with highly competitive academic profiles. UCI is also ranked No. 2 by U.S. News & World Report for social mobility, which takes into account the graduation rate of students awarded Pell Grants. Orange County’s second-largest employer, UCI generates an annual economic impact on the county of $7 billion. http://www.uci.edu/
2013
Associate Scientist
Sep 2013
At BASF, we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers’ green transformation. We combine economic success with environmental protection and social responsibility. Around 108,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of around €60 billion in 2025. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States.
Credits: https://www.basf.com/global/en/legal/credits
Data protection information: https://www.basf.com/global/en/legal/data-protection-at-basf.html
2012
Research Associate
Dec 2012
We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.
For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl
